10 results about "PR - Progesterone receptor" patented technology

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.

The present invention provides methods of female contraception, the methods comprising administering an effective amount of a combination of a progesterone receptor agonist and a cyclooxygenase-2 inhibitor in each of two doses, the first dose is administered within about 24 hours before or after a first act of sexual intercourse and the second dose is administered between about 36 hours and about 60 hours after the first dose.

The present disclosure provides a cancer treatment that uses an extracellular secretion. In a specific embodiment, the present disclosure provides a cancer treatment that uses a combination of an extracellular secretion and an ascorbic acid component. The present disclosure provides uses, methods, combinations, or compositions for the treatment of cancer. In one embodiment, the cancer may be breast cancer (including triple-negative breast cancer lacking estrogen receptors, progesterone receptors, and HER2). The subject to be treated includes mammals such as humans, mice, rats, cats, and dogs.

The present disclosure provides a cancer treatment that uses BRMs. A specific embodiment provides a cancer treatment that uses a combination of BRMs and an ascorbic acid component. The present disclosure provides a use, method, combination, composition, or the like for cancer treatment. According to one embodiment, the cancer may be breast cancer (including triple-negative breast cancer, which lacks estrogen receptors, progesterone receptors, and HER2). The subject to be treated can be a mammal such as a human, a mouse, a rat, a cat, or a dog.

The present invention provides a method and composition for reversibly localizing proteins to the outer portion of the cell surface. [Solution] Essentially, the protein must include a hormone receptor such as estrogen receptor alpha or progesterone receptor in addition to the transmembrane domain. The compositions provided herein may include nucleic acids encoding the polypeptide of interest and the ligand-binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.

Device (2) and method for determining a value quantifying a risk of relapse of breast cancer for a patient A device for determining a value quantifying a risk of relapse of breast cancer for a patient comprises a data storage (114) adapted to store patient data associating, for each given patient at a least one whole histological slide image and patient clinical data comprising at least a tumor size, a number of positive lymph nodes, a tumor grade, and progesterone receptor (PR) positivity value, a feature extractor (1210, 1220) arranged to receive a whole histological slide image and associated patient clinical data, to derive tumor architecture features comprising a tumor area, an invasive tumor nest density, a tumor density at the invasive front, and an in situ tumor nest density, tumor microenvironment features comprising a border composition of in situ tumor, a variance of healthy gland size, an inflammatory stroma area, and an average nuclei size of stromal cells, and mitosis features comprising a mitotic hotspot count and a mitotic density, and to return a patient feature vector comprising said tumor architecture features, said tumor microenvironment features, said mitosis features, and features derived from said associated patient clinical data, a risk classifier (1230) using a machine learning module which is arranged to receive a patient feature vector as an input and to return a value quantifying a risk of relapse of breast cancer for a patient, said machine learning module having been trained with a dataset of labelled patient feature vectors and being arranged to return a risk value. This device is arranged to receive a set of patient data of a given patient, to provide at least some of said given patient's whole histological slide image and said given patient's clinical data as inputs to the feature extractor, to provide at least some of the resulting patient feature vectors to the risk classifier, and to return a value quantifying a risk of relapse of breast cancer for a patient for said given patient based on the outputs of the risk classifier.